GE HealthCare receives CE mark for 128cm total body PET/CT
GE HealthCare has secured CE mark approval for its Omni 128cm total body positron emission tomography/computed tomography system, designed to advance cancer diagnosis, staging and therapeutic planning through enhanced molecular imaging capabilities. The next-generation platform addresses growing demand for whole-body PET/CT imaging as global cancer rates are projected to increase 77 per cent by 2050.
Single bed position imaging transforms workflow efficiency
The system accommodates head-to-thigh imaging in a single bed position across a wide patient demographic, compared with traditional systems requiring five to six bed positions. This design enables accelerated scan times and streamlined workflows whilst supporting ultra-low dose scans, multi-organ dynamic imaging and imaging of slow-decaying, low-activity tracers.
“Our commitment to precision health is rooted in innovation that also aims to anticipate the future of care,” said Jean-Luc Procaccini, president and CEO of molecular imaging and computed tomography at GE HealthCare. “With our Omni 128cm total body PET/CT system, we’re not just advancing imaging – we’re building a platform that empowers clinicians to deliver personalised, efficient and impactful care.”
Clinical applications span oncology and research domains
The technology’s ultra-high sensitivity and spatial resolution support imaging across multiple clinical applications, including advanced prostate cancer treatment monitoring. The non-invasive platform quantifies biological processes at the cellular level, facilitating early disease identification and treatment planning.
“PET/CT has transformed our ability to visualise disease at the cellular level, offering insights that were once out of reach,” said Prof Michael Hofman, nuclear medicine physician and head of the PET/CT programme at Melbourne’s Peter MacCallum Cancer Centre. “With the Omni 128cm total body PET/CT system, we’re entering a new phase of possibility – one where faster scans and broader imaging coverage could redefine how we approach translational research and accelerate the development of targeted therapies.”
Paediatric imaging benefits from dose reduction capabilities
The system’s ultra-low dose scanning capability holds particular significance for paediatric populations, where minimising radiation exposure remains a clinical priority. The platform’s speed and precision may reduce anaesthesia requirements in paediatric scans whilst enabling confident early diagnoses.
“This next-generation PET/CT technology is engineered to deliver exceptional sensitivity and resolution – capabilities that could reshape how we approach molecular imaging,” said Ken Herrmann, MD, director and chair of the department of nuclear medicine at Universitätsklinikum Essen.
Research applications accelerate theranostic development
The Omni 128cm system supports advanced research applications spanning novel PET tracer development, new clinical pathway evaluation and emerging theranostic agent assessment. Integration with GE HealthCare’s MIM software solutions provides advanced quantitation tools and streamlined workflows for diagnostic confidence and operational efficiency.
The platform leverages NVIDIA’s accelerated computing technology to optimise reconstruction processes, reducing image generation time for timely clinical diagnoses. The CE mark milestone coincides with GE HealthCare’s 25-year history in PET/CT innovation, from launching the industry’s first commercially available PET/CT system, Discovery LS, to this total body solution.
The Omni 128cm system with 128cm axial field of view is CE marked and available for sale in EU member states. The system is not approved or cleared by the US FDA and is not available for sale in the US and other non-EU member states.
- For more information, visit: https://www.gehealthcare.co.uk/products/molecular-imaging
